Post-Market Data
Real World Evidence
Need regulated post-market follow-up too? See our Post Market Surveillance page - or scope one combined programme via enterprise.
What you get
Evidence built for the real world
Multi-site, multi-country
Aggregate data from any number of clinics, hospitals or geographies into a single observational dataset.
100% compliance is possible
Branded, frictionless patient experience with timely reminders - the Citius Arthrosamid programme reached 100% compliance.
Validated PROMs
WOMAC, KOOS, Oxford Knee, EQ-5D, VAS and more - scored automatically and timestamped at every interval.
Live dashboards
Track recruitment, completion rates and headline outcome scores while the study is still running.
Clinician-friendly capture
Anatomical and clinical assessment data captured in seconds at the point of care - not after clinic.
Marketing-ready outputs
Charts, narrative and case studies you can share with KOLs, sales teams and prospective customers.
Case Study
Arthrosamid - Citius Retired Athletes
Contura Orthopaedics programme, live from May 2025.
Patient Watch powers the Citius Retired Athletes Program for Arthrosamid knee osteoarthritis treatment. The result: a 38.5-point WOMAC improvement at 4 weeks - the best performing Arthrosamid study globally - with 100% patient compliance over 12 months of follow-up.
- • QR-code onboarding straight from the waiting room
- • WOMAC, Oxford Knee, EQ-5D and VAS at baseline, 3, 6, 9 and 12 months
- • Live dashboards for the clinical and commercial teams
Case Study
IBSA and Sinovial - multi-centre knee OA programme
Study Start: May 2026
Patient Watch is supporting IBSA and the Sinovial project with a 100-patient real-world programme across 10 clinicians, capturing the Oxford Knee Score and EQ-5D alongside injection and safety data. We are helping the team secure the correct licensed use of these copyright-protected PROMs (Oxford University Innovation and EuroQol) so governance, publications and commercial use stay compliant.
- • Oxford Knee Score and EQ-5D at programme timepoints, with automated scoring and audit trail
- • Follow-up aligned to the Sinovial schedule: baseline, 1 week, 3 months and 6 months
- • Health questionnaire, pain tracking and adverse-event capture for a complete RWE dataset
- • Cohort dashboards and exports for medical, regulatory and market access stakeholders
Ask us about running a licensed PROM programme for your own injection or device rollout.
Case Study
Anika Therapeutics - Cingal real-world outcomes
Programme start: July 2026
Patient Watch is supporting Anika with a UK and Germany real-world programme for Cingal knee osteoarthritis. Up to 100 patients across participating clinicians capture WOMAC at baseline, 3, 6, 9 and 12 months - giving medical affairs and market teams outcome data from real clinics, not just trial sites.
- • WOMAC at five timepoints with automated scoring and SMS or email reminders
- • English and German patient journeys, aligned to each country's programme
- • Clinician caseload views plus sponsor dashboards split by market
- • Exportable cohort data for publications, NHS conversations and post-market follow-up
Ask us about a branded real-world programme for your injection or device portfolio.
Generate evidence that sells
Tell us about the product, indication and timelines and we'll scope a study that delivers usable data.